ROS1der risk and COVID-19

Updated: Feb 15

At the ASCO 2020 conference, two registries reported on efforts to track cancer patient outcomes. The research suggests that lung cancer patients infected with COVID-19 have worse outcomes.


COVID-19 and Cancer Consortium found that patients with actively progressing cancer were five times more likely to die within 30 days of a COVID-19 diagnosis compared to patients who were in remission or had no evidence of disease. (Read finding. )


A second registry effort, Thoracic cancERs international coVid 19 cOLlaboraTion reported that patients receiving chemotherapy within three months of a diagnosis of COVID-19, either alone or in combination, fared the worst, with a significantly increased risk of dying (64%) compared to those who did not receive chemotherapy.


8 views0 comments